Long‐term outcomes of thalidomide in refractory Crohn's disease
Authors:
- 15 December 2014
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 41 (5) , 429-437
Abstract
Summary: Background: Several open‐label and retrospective studies have indicated that thalidomide may be beneficial in patients with refractory Crohn's disease (CD).Aim: To report our long‐term experience with the use of thalidomide for adults with refractory Crohn's disease.Methods: We conducted a retrospective study of long‐term clinical and safety outcomes among adults treated with thalidomide for refractory Crohn's disease. Response was defined as a clinician's assessment of improvement after at least 7 days treatment of one or more of the following: bowel movement frequency, fistula output, rectal bleeding, abdominal pain, extraintestinal manifestations, or well‐being. Remission required all of the following: P = 0.01). An adverse event occurred in 68% of patients. Approximately one‐third of patients (38%) experienced neuropathy.Conclusions: Thalidomide appears to be safe and effective in some patients with refractory Crohn's disease. Although side effects may limit long‐term use, thalidomide has potential to induce significant clinical responses.Keywords
This publication has 33 references indexed in Scilit:
- Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC)American Journal of Physiology-Gastrointestinal and Liver Physiology, 2010
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2009
- Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long‐term resultsAlimentary Pharmacology & Therapeutics, 2007
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's diseaseGut, 2002
- Thalidomide impairment of trinitrobenzene sulphonic acid‐induced colitis in the rat–role of endothelial cell‐leukocyte interactionBritish Journal of Pharmacology, 2001
- Thalidomide for the Treatment of AIDS-Associated WastingAIDS Research and Human Retroviruses, 2000
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.Journal of Experimental Medicine, 1993